| Variables |
Frequency(n) |
Percent (%) |
| WHO clinical stage |
Stage I |
207 |
61.2 |
| Stage II |
58 |
17.2 |
| Stage III |
66 |
19.5 |
| Stage IV |
7 |
2.1 |
| CD4+ T cell count |
<200 cells/μl |
56 |
16.6 |
| 200-350 cells/μl |
80 |
23.7 |
| 351-500 cells/μl |
85 |
25.1 |
| >500 cells/μl |
117 |
34.6 |
| Anemia status |
Normal |
244 |
72.2 |
| Anemic |
94 |
27.8 |
| Current/past OI in the past six months |
No |
190 |
56.2 |
| Yes |
Problems |
148 |
43.8 |
| |
Acute/chronic Diarrhea |
53 |
15.7 |
| Tuberculosis |
86 |
25.4 |
| Oral thrush |
18 |
5.3 |
| Oral ulcer |
11 |
3.3 |
| Pneumonia |
12 |
3.6 |
| Zoster |
1 |
0.3 |
| Pneumocystis carinii |
2 |
0.6 |
| ART regimens |
1a (d4T+3TC+NVP) |
7 |
2.1 |
| 1c (AZT+3TC+NVP) |
141 |
41.7 |
| 1d (AZT+3TC+EFV) |
15 |
4.4 |
| 1e (TDF+3TC+EFV) |
142 |
42.0 |
| 1f (TDF+3TC+NVP) |
29 |
8.6 |
| 2b (TDF+3TC+LPV/r) |
4 |
1.2 |
| Drug adherence |
Good |
310 |
91.7 |
| Fair |
20 |
5.9 |
| Poor |
8 |
2.4 |
| Dietary counseling |
No |
155 |
45.9 |
| Yes |
183 |
54.1 |
| Organizational support other than medication |
No |
294 |
87 |
| Economical support |
7 |
2.1 |
| RUTF |
28 |
8.3 |
| Economical and RUTF |
9 |
2.7 |
| Household dietary diversity |
Inadequate |
131 |
38.8 |
| Adequate |
207 |
61.2 |
|
| N.B: AZT: Zidovudine; d4T: Stavudine; EFV: Efavirenz; NVP: Nevirapine; TDF: Tenofovir; 3TC: Lamivudine; LPV/r: Lopinavir + Ritonavir |
| Table 2: Clinical profiles and ART status of the study participants at Butajira Hospital, Southern Ethiopia, 2014, (n=338). |